Key Details
Price
$1.61Annual ROE
-156.66%Beta
0.53Events Calendar
Next earnings date:
May 9, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 7, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jul 18, 2024Analyst ratings
Recent major analysts updates
Aug 16, 23 HC Wainwright & Co.
NeutralAug 15, 23 Laidlaw & Co.
HoldMay 15, 23 HC Wainwright & Co.
BuyMay 4, 22 Wells Fargo
OverweightNov 9, 21 Raymond James
Market PerformAug 10, 21 Raymond James
Market PerformMay 7, 21 Raymond James
OutperformMar 12, 21 Jefferies
HoldMar 1, 21 HC Wainwright & Co.
NeutralJun 19, 20 Jefferies
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Price
Market cap
Technical
Dividend
Alaunos Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Leverage
Risk & Stability
Balance Sheet
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Assets
Equity
Liabilities
Debt
Expenses
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
TCRT
Zacks Investment ResearchAugust 16, 2023
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
TCRT
GlobeNewsWireMarch 29, 2023
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
FAQ
- What is the ticker symbol for Alaunos Therapeutics?
- Does Alaunos Therapeutics pay dividends?
- What sector is Alaunos Therapeutics in?
- What industry is Alaunos Therapeutics in?
- What country is Alaunos Therapeutics based in?
- When did Alaunos Therapeutics go public?
- Is Alaunos Therapeutics in the S&P 500?
- Is Alaunos Therapeutics in the NASDAQ 100?
- Is Alaunos Therapeutics in the Dow Jones?
- When was Alaunos Therapeutics's last earnings report?
- When does Alaunos Therapeutics report earnings?
- Should I buy Alaunos Therapeutics stock now?
What is the ticker symbol for Alaunos Therapeutics?
The ticker symbol for Alaunos Therapeutics is NASDAQ:TCRT
Does Alaunos Therapeutics pay dividends?
No, Alaunos Therapeutics does not pay dividends
What sector is Alaunos Therapeutics in?
Alaunos Therapeutics is in the Healthcare sector
What industry is Alaunos Therapeutics in?
Alaunos Therapeutics is in the Biotechnology industry
What country is Alaunos Therapeutics based in?
Alaunos Therapeutics is headquartered in United States
When did Alaunos Therapeutics go public?
Alaunos Therapeutics's initial public offering (IPO) was on August 24, 2005
Is Alaunos Therapeutics in the S&P 500?
No, Alaunos Therapeutics is not included in the S&P 500 index
Is Alaunos Therapeutics in the NASDAQ 100?
No, Alaunos Therapeutics is not included in the NASDAQ 100 index
Is Alaunos Therapeutics in the Dow Jones?
No, Alaunos Therapeutics is not included in the Dow Jones index
When was Alaunos Therapeutics's last earnings report?
Alaunos Therapeutics's most recent earnings report was on Nov 14, 2024
When does Alaunos Therapeutics report earnings?
The next expected earnings date for Alaunos Therapeutics is May 9, 2025
Should I buy Alaunos Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions